Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using Lu-177-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).

Kim N. Chi,Ur Metser,Johannes Czernin,Jeremie Calais,Vikas Prasad,Matthias Eiber,Neal D. Shore,Jessica Jensen,Neil Eric Fleshner,Scott T. Tagawa,A. Oliver Sartor

Journal of Clinical Oncology（2021）

引用 6|浏览6

暂无评分

摘要

TPS5087Background: Treatment options with minimal toxicity and novel mechanisms of action are urgently needed to improve clinical outcomes from mCRPC. Prostate-specific membrane antigen (PSMA)-targ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要